References
Axtell RC, Raman C, Steinman L, Type L. I interferons: beneficial in Th1 and detrimental in Th17 autoimmunity. Clin Rev Allergy Immunol 2013; 44: 114–20.
Navne JE, Hedegaard U, Bygum A. [Activation of psoriasis in patients undergoing treatment with interferon-beta]. Ugeskr Laeger 2005; 167: 2903–4.
Webster GF, Knobler RL, Lublin FD, Kramer EM, Hochman LR. Cutaneous ulcerations and pustular psoriasis flare caused by recombinant interferon beta injections in patients with multiple sclerosis. J Am Acad Dermatol 1996; 34: 365–7.
Lopez-Lerma I, Iranzo P, Herrero C. New-onset psoriasis in a patient treated with interferon beta-1a. Br J Dermatol 2009; 160: 716–7.
La Mantia L, Capsoni F. Psoriasis during interferon beta treatment for multiple sclerosis. Neurol Sci 2010; 31: 337–9.
Afshar M, Martinez AD, Gallo RL, Hata TR. Induction and exacerbation of psoriasis with Interferon-alpha therapy for hepatitis C: a review and analysis of 36 cases. J Eur Acad Dermatol Venereol 2013; 27: 771–8.
Buttmann M, Goebeler M, Toksoy A, et al. Subcutaneous interferon-beta injections in patients with multiple sclerosis initiate inflammatory skin reactions by local chemokine induction. J Neuroimmunol 2005; 168: 175–82.
Gottlieb AB, Luster AD, Posnett DN, Carter DM. Detection of a gamma interferon-induced protein IP-10 in psoriatic plaques. J Exp Med 1988; 168: 941–8.
Antonelli A, Fallahi P, Delle Sedie A, et al. High values of Th1 (CXCL10) and Th2 (CCL2) chemokines in patients with psoriatic arthtritis. Clin Exp Rheumatol 2009; 27: 22–7.
Axtell RC, Raman C, Steinman L. Interferon- exacerbates Th17-mediated inflammatory disease. Trends Immunol 2011; 32: 272–7.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Amschler, K., Meyersburg, D., Kitze, B. et al. Onset of psoriasis upon interferon beta treatment in a multiple sclerosis patient. Eur J Dermatol 26, 211–212 (2016). https://doi.org/10.1684/ejd.2015.2602
Published:
Issue Date:
DOI: https://doi.org/10.1684/ejd.2015.2602